TY - JOUR
T1 - Phosphinic acid functionalized polyazacycloalkane chelators for radiodiagnostics and radiotherapeutics
T2 - Unique characteristics and applications
AU - Notni, Johannes
AU - Šimeček, Jakub
AU - Wester, Hans Jürgen
PY - 2014/6
Y1 - 2014/6
N2 - Given the wide application of positron emission tomography (PET), positron-emitting metal radionuclides have received much attention recently. Of these, gallium-68 has become particularly popular, as it is the only PET nuclide commercially available from radionuclide generators, therefore allowing local production of PET radiotracers independent of an on-site cyclotron. Hence, interest in optimized bifunctional chelators for the elaboration of 68Ga-labeled bioconjugates has been rekindled as well, resulting in the development of improved triazacyclononane-triphosphinate (TRAP) ligand structures. The most remarkable features of these ligands are unparalleled selectivity for GaIII, rapid GaIII complexation kinetics, extraordinarily high thermodynamic stability, and kinetic inertness of the respective GaIII chelates. As a result, TRAP chelators exhibit very favorable 68Ga-labeling properties. Based on the scaffolds NOPO (1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)phosphinic acid]-7-[methylene(2-carboxyethyl)phosphinic acid]) and TRAP-Pr, tailored for convenient preparation of 68Ga-labeled monomeric and multimeric bioconjugates, a variety of novel 68Ga radiopharmaceuticals have been synthesized. These include bisphosphonates, somatostatin receptor ligands, prostate-specific membrane antigen (PSMA)-targeting peptides, and cyclic RGD pentapeptides, for in vivo PET imaging of bone, neuroendocrine tumors, prostate cancer, and integrin expression, respectively. Furthermore, TRAP-based 68Ga-labeled gadolinium(III) complexes have been proposed as bimodal probes for PET/MRI, and a cyclen-based analogue of TRAP-Pr has been suggested for the elaboration of targeted radiotherapeutics comprising radiolanthanide ions. Thus, polyazacycloalkane-based polyphosphinic acid chelators are a powerful toolbox for pharmaceutical research, particularly for the development of 68Ga radiopharmaceuticals. Radiopharmaceutical toolbox: Polyazacycloalkanes with methylene(phosphinic acid) N-substituents such as functionalized triazacyclononane triphosphinates (shown), are very useful bifunctional chelators for radiopharmaceuticals, such as gallium-68-labeled peptide conjugates or radiolanthanide-based therapeutics.
AB - Given the wide application of positron emission tomography (PET), positron-emitting metal radionuclides have received much attention recently. Of these, gallium-68 has become particularly popular, as it is the only PET nuclide commercially available from radionuclide generators, therefore allowing local production of PET radiotracers independent of an on-site cyclotron. Hence, interest in optimized bifunctional chelators for the elaboration of 68Ga-labeled bioconjugates has been rekindled as well, resulting in the development of improved triazacyclononane-triphosphinate (TRAP) ligand structures. The most remarkable features of these ligands are unparalleled selectivity for GaIII, rapid GaIII complexation kinetics, extraordinarily high thermodynamic stability, and kinetic inertness of the respective GaIII chelates. As a result, TRAP chelators exhibit very favorable 68Ga-labeling properties. Based on the scaffolds NOPO (1,4,7-triazacyclononane-1,4-bis[methylene(hydroxymethyl)phosphinic acid]-7-[methylene(2-carboxyethyl)phosphinic acid]) and TRAP-Pr, tailored for convenient preparation of 68Ga-labeled monomeric and multimeric bioconjugates, a variety of novel 68Ga radiopharmaceuticals have been synthesized. These include bisphosphonates, somatostatin receptor ligands, prostate-specific membrane antigen (PSMA)-targeting peptides, and cyclic RGD pentapeptides, for in vivo PET imaging of bone, neuroendocrine tumors, prostate cancer, and integrin expression, respectively. Furthermore, TRAP-based 68Ga-labeled gadolinium(III) complexes have been proposed as bimodal probes for PET/MRI, and a cyclen-based analogue of TRAP-Pr has been suggested for the elaboration of targeted radiotherapeutics comprising radiolanthanide ions. Thus, polyazacycloalkane-based polyphosphinic acid chelators are a powerful toolbox for pharmaceutical research, particularly for the development of 68Ga radiopharmaceuticals. Radiopharmaceutical toolbox: Polyazacycloalkanes with methylene(phosphinic acid) N-substituents such as functionalized triazacyclononane triphosphinates (shown), are very useful bifunctional chelators for radiopharmaceuticals, such as gallium-68-labeled peptide conjugates or radiolanthanide-based therapeutics.
KW - chelates
KW - gallium-68
KW - macrocycles
KW - phosphinic acid
KW - positron emission tomography
KW - radiopharmaceuticals
UR - http://www.scopus.com/inward/record.url?scp=84901499013&partnerID=8YFLogxK
U2 - 10.1002/cmdc.201400055
DO - 10.1002/cmdc.201400055
M3 - Review article
C2 - 24700633
AN - SCOPUS:84901499013
SN - 1860-7179
VL - 9
SP - 1107
EP - 1115
JO - ChemMedChem
JF - ChemMedChem
IS - 6
ER -